Sinus bradycardia associated with daclizumab in liver transplant recipients: report of 3 cases.
Daclizumab is a commonly used immunosuppressive agent for prophylaxis of solid organ rejection. Although rare, the cardiovascular adverse effects of daclizumab include sinus tachycardia, hypotension, and hypertension. Here, we report 3 patients who developed significant and prolonged sinus bradycardia after receiving daclizumab following orthotopic liver transplant. Daclizumab should be considered a possible cause of bradycardia following its administration in orthotopic liver transplant.
Bassily-Marcus
Adel
A
Department of Surgery, Division of Critical Care Medicine, The Mount Sinai School of Medicine, New York, NY 10029, USA. adel.bassily-marcus@mssm.edu
Kohli-Seth
Roopa
R
Leibowitz
Andrew
A
Murgolo
Victor
V
Oropello
John
J
Manasia
Anthony
A
Benjamin
Ernest
E
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001919:Bradycardia / Q000139:chemically induced*; D006528:Carcinoma, Hepatocellular / Q000601:surgery; D015209:Cholangitis, Sclerosing / Q000601:surgery; D000077561:Daclizumab; D005260:Female; D006509:Hepatitis B / Q000150:complications; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008103:Liver Cirrhosis / Q000601:surgery; D008107:Liver Diseases / Q000601:surgery; D008113:Liver Neoplasms / Q000601:surgery; D016031:Liver Transplantation; D008297:Male
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab